JP2010513434A5 - - Google Patents

Download PDF

Info

Publication number
JP2010513434A5
JP2010513434A5 JP2009542194A JP2009542194A JP2010513434A5 JP 2010513434 A5 JP2010513434 A5 JP 2010513434A5 JP 2009542194 A JP2009542194 A JP 2009542194A JP 2009542194 A JP2009542194 A JP 2009542194A JP 2010513434 A5 JP2010513434 A5 JP 2010513434A5
Authority
JP
Japan
Prior art keywords
oxy
azoniabicyclo
octane
alkyl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009542194A
Other languages
English (en)
Japanese (ja)
Other versions
JP4604129B2 (ja
JP2010513434A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2007/004817 external-priority patent/WO2008075005A1/en
Publication of JP2010513434A publication Critical patent/JP2010513434A/ja
Publication of JP2010513434A5 publication Critical patent/JP2010513434A5/ja
Application granted granted Critical
Publication of JP4604129B2 publication Critical patent/JP4604129B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009542194A 2006-12-19 2007-12-17 ムスカリン受容体アンタゴニストとしてのキヌクリジノール誘導体 Expired - Fee Related JP4604129B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87063806P 2006-12-19 2006-12-19
PCT/GB2007/004817 WO2008075005A1 (en) 2006-12-19 2007-12-17 Quinuclidinol derivatives as muscarinic receptor antagonists

Publications (3)

Publication Number Publication Date
JP2010513434A JP2010513434A (ja) 2010-04-30
JP2010513434A5 true JP2010513434A5 (enExample) 2010-06-17
JP4604129B2 JP4604129B2 (ja) 2010-12-22

Family

ID=39166793

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009542194A Expired - Fee Related JP4604129B2 (ja) 2006-12-19 2007-12-17 ムスカリン受容体アンタゴニストとしてのキヌクリジノール誘導体

Country Status (22)

Country Link
US (1) US20100113510A1 (enExample)
EP (1) EP2121137B1 (enExample)
JP (1) JP4604129B2 (enExample)
KR (1) KR20090094460A (enExample)
CN (1) CN101610813A (enExample)
AR (1) AR064414A1 (enExample)
AT (1) ATE555111T1 (enExample)
AU (1) AU2007336054A1 (enExample)
BR (1) BRPI0721039A2 (enExample)
CA (1) CA2672446A1 (enExample)
CL (1) CL2007003690A1 (enExample)
CO (1) CO6180439A2 (enExample)
EC (1) ECSP099394A (enExample)
ES (1) ES2385681T3 (enExample)
IL (1) IL199015A0 (enExample)
MX (1) MX2009006018A (enExample)
NO (1) NO20092689L (enExample)
PE (1) PE20081837A1 (enExample)
RU (1) RU2009120229A (enExample)
TW (1) TW200831507A (enExample)
UY (1) UY30803A1 (enExample)
WO (1) WO2008075005A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200825084A (en) 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
GB0808707D0 (en) * 2008-05-13 2008-06-18 Argenta Discovery Ltd New compounds 275
WO2009138707A1 (en) 2008-05-13 2009-11-19 Astrazeneca Ab Quinuclidine derivatives as muscarinic m3 receptor antagonists
GB0811099D0 (en) * 2008-06-17 2008-07-23 Astrazeneca Ab New combination 376
GB0811100D0 (en) * 2008-06-17 2008-07-23 Astrazeneca Ab New combination
WO2009153536A1 (en) * 2008-06-17 2009-12-23 Argenta Discovery Limited 1-aza-bicyclo [2.2.2] octane derivatives useful as muscarinic receptor antagonists
WO2010008341A1 (en) * 2008-07-16 2010-01-21 Astrazeneca Ab A combination of (a) glucocorticoid receptor modulator and (b) a muscarinic antagonist
EP2206712A1 (en) * 2008-12-23 2010-07-14 CHIESI FARMACEUTICI S.p.A. "Alkaloid aminoester derivatives and medicinal composition thereof"
TW201036957A (en) 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
WO2010144043A1 (en) * 2009-06-12 2010-12-16 Astrazeneca Ab A novel 4-methylbenzenesulphonate salt and a process for preparing a pharmaceutical composition comprising the salt
SG178174A1 (en) 2009-07-31 2012-03-29 Cadila Healthcare Ltd Novel compounds as modulators of glucocorticoid receptors
WO2011073662A1 (en) 2009-12-17 2011-06-23 Astrazeneca Ab Combination of a benzoxazinone and a further agent for treating respiratory diseases
ES2545812T3 (es) * 2010-06-22 2015-09-16 Chiesi Farmaceutici S.P.A. Derivados aminoéster de alcaloides y composición medicinal de estos
BR112012031967A2 (pt) * 2010-06-22 2019-09-24 Chiesi Farm Spa composto, uso de um composto, combinação de um composto e composição farmacêutica
WO2013098145A1 (en) 2011-12-30 2013-07-04 Chiesi Farmaceutici S.P.A. Quinuclidine esters of 1-azaheterocyclylacetic acid as antimuscarinic agents, process for their preparation and medicinal compositions thereof
ES2726664T3 (es) * 2013-07-13 2019-10-08 Beijing Shuobai Pharmaceutical Co Ltd Compuestos de quinina e isómeros ópticos, procedimiento de preparación y uso médico de los mismos

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8334494D0 (en) 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
GB8923590D0 (en) * 1989-10-19 1989-12-06 Pfizer Ltd Antimuscarinic bronchodilators
GR1001529B (el) 1990-09-07 1994-03-31 Elmuquimica Farm Sl Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης.
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
IL125686A (en) 1996-02-13 2002-11-10 Zeneca Ltd Quinazoline derivatives, processes for their preparation, pharmaceutical preparations containing them and their use in the manufacture of a drug with an anti-angiogenic effect and / or an effect of reducing vascular permeability
IL125954A (en) 1996-03-05 2003-06-24 Zeneca Ltd Quinazoline derivatives, processes for their preparation, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments having an antiangiogenic and/or vascular permeability reducing effect
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
JP2003535078A (ja) 2000-05-31 2003-11-25 アストラゼネカ アクチボラグ 血管損傷活性のあるインドール誘導体
GB0015876D0 (en) 2000-06-28 2000-08-23 Novartis Ag Organic compounds
CA2411160A1 (en) 2000-07-07 2002-01-17 Angiogene Pharmaceuticals Limited Colchinol derivatives as vascular damaging agents
RU2003103603A (ru) 2000-07-07 2004-08-20 Энджиоджен Фармасьютикалз Лимитед (Gb) Производные колхинола в качестве ингибиторов ангиогенеза
DE60224172T2 (de) 2001-03-22 2008-12-04 Glaxo Group Ltd., Greenford Formanilid-derivative als beta2-adrenorezeptor-agonisten
KR100831534B1 (ko) 2001-04-30 2008-05-22 글락소 그룹 리미티드 17.알파 위치에 시클릭 에스테르기를 지닌 항염증성의안드로스탄의 17.베타.-카르보티오에이트 에스테르 유도체
US20030229058A1 (en) 2001-11-13 2003-12-11 Moran Edmund J. Aryl aniline beta2 adrenergic receptor agonists
TWI249515B (en) 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
CA2499314C (en) 2002-10-11 2010-08-24 Pfizer Inc. Indole derivatives as beta-2 agonists
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
AR044134A1 (es) * 2003-05-02 2005-08-24 Novartis Ag Derivados de quinuclidina, metodo de preparacion y composiciones farmaceuticas.
CN100445281C (zh) * 2003-05-02 2008-12-24 诺瓦提斯公司 与毒蕈碱性m3受体结合的奎宁环衍生物
EP1684767A1 (en) 2003-11-03 2006-08-02 Norton Healthcare Limited Soft steroid compositions for use in dry powder inhalers
WO2006046916A1 (en) 2004-10-29 2006-05-04 Astrazeneca Ab Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflammatory diseases
GB0424284D0 (en) * 2004-11-02 2004-12-01 Novartis Ag Organic compounds
TW200722418A (en) * 2005-04-20 2007-06-16 Astrazeneca Ab Novel compounds

Similar Documents

Publication Publication Date Title
JP2010513434A5 (enExample)
JP7398391B2 (ja) N-[4-オキソ-2,3-ジヒドロ-1,5-ベンズオキサゼピン-3-イル]-5,6-ジヒドロ-4H-ピロロ[1,2-b]ピラゾール-2-カルボキサミド誘導体及び例えば過敏性腸症候群(IBS)を処置するためのRIP1キナーゼ阻害剤としての関連化合物
RU2746129C2 (ru) Биарильные монобактамные соединения и способы их применения для лечения бактериальных инфекций
JP2005533826A5 (enExample)
JP4505227B2 (ja) 1−アルキル−1−アゾニアビシクロ[2.2.2]オクタンカルバメート誘導体およびムスカリンレセプターアンタゴニストとしてのそれらの使用
RU2009120229A (ru) Производные хинуклидинола в качестве антагонистов мускариновых рецепторов
US7718670B2 (en) Quinuclidine amide derivatives
JP4853918B2 (ja) グリシン輸送阻害剤としての三環式化合物の使用
RU2399620C2 (ru) Производные хинуклидина и их применение в качестве антагонистов мускариновых рецепторов м3
JP6505023B2 (ja) Cnsおよび他の障害を治療するための、pde4アイソザイムの阻害薬としてのアザベンゾイミダゾール化合物
RU2004104625A (ru) Аналоги простагландинов в качестве агонистов рецептора ep4
TWI629276B (zh) 咪唑并嗒化合物
JP2008509187A5 (enExample)
JP2008500990A5 (enExample)
JP7367038B2 (ja) Lpa1受容体のイメージングのための放射性リガンド
WO2015196071A9 (en) Compounds, compositions and methods of increasing cftr activity
JP2008500988A5 (enExample)
CN1152870A (zh) 杂环化合物作为多巴胺d3配位体的用途
JP2010509391A5 (enExample)
CA2401502A1 (en) Carboxylic acid derivatives as ip antagonists
WO2016115090A1 (en) Compounds, compositions and methods for increasing cftr activity
JP5552121B2 (ja) ロイコトリエン産生のインドリジン阻害剤
AU2013358591A1 (en) Pyrimido [4,5-b]quinoline-4,5 (3H,10H)-diones as nonsense mutation suppressors
JP2010535858A5 (enExample)
TW201625591A (zh) 吖丁啶基氧苯基吡咯啶化合物